Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon TLR7/8 Agonist +/- Pembrolizumab in Advanced Solid Tumors
NCT04799054Phase 2Terminated
- Sponsor
- Ascendis Pharma
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ACP-017 in solid tumor, head and neck squamous cell carcinoma (HNSCC), HPV-associated cancer, melanoma, cutaneous squamous cell carcinoma (cSCC), sponsored by Ascendis Pharma. Started Mar 2021; status: terminated.
02
Drugs
ACP-017
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)HPV-associated cancermelanomacutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04799054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799054.